Bleakley Financial Group LLC Has $46,000 Position in Precigen, Inc. (NASDAQ:PGEN)

Bleakley Financial Group LLC reduced its stake in Precigen, Inc. (NASDAQ:PGEN) by 23.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,245 shares of the biotechnology company’s stock after selling 10,731 shares during the period. Bleakley Financial Group LLC’s holdings in Precigen were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new stake in Precigen during the 1st quarter worth approximately $25,000. Cresset Asset Management LLC bought a new stake in shares of Precigen in the 1st quarter valued at $25,000. Public Employees Retirement System of Ohio bought a new stake in shares of Precigen in the 1st quarter valued at $28,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Precigen by 338.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,788 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 22,227 shares in the last quarter. Finally, Diversified Trust Co bought a new stake in shares of Precigen in the 4th quarter valued at $39,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Stock Down 2.9 %

PGEN opened at $1.36 on Wednesday. The firm’s fifty day moving average price is $1.46 and its two-hundred day moving average price is $1.31. Precigen, Inc. has a 1 year low of $0.84 and a 1 year high of $1.88.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $2.03 million. Precigen had a negative return on equity of 55.47% and a negative net margin of 1,540.63%. Sell-side analysts predict that Precigen, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Ratings Changes

PGEN has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Precigen in a research note on Wednesday, March 20th. StockNews.com upgraded shares of Precigen to a “sell” rating in a research note on Tuesday, March 26th. JMP Securities restated a “market outperform” rating and set a $14.00 price target on shares of Precigen in a research note on Wednesday, March 20th. Finally, JPMorgan Chase & Co. lowered shares of Precigen from a “neutral” rating to an “underweight” rating in a research note on Friday, March 22nd.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.